200
jewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD,
Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor ef-
fects. Proc Natl Acad Sci U S A 2002; 99 (17): 11393-11398.
33. [No authors listed]. Aflibercept: AVE 0005, AVE 005, AVE0005,
VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
Drugs R D 2008; 9 (4): 261-269.
34. Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT.
Combinatory inhibition of VEGF and FGF2 is superior to solitary
VEGF inhibition in an in vitro model of RPE-induced angiogen-
esis. Graefes Arch Clin Exp Ophthalmol 2009; 247 (6): 767-773.
35. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P,
Lutty GA. Pigment epithelium-derived factor (PEDF) and vascular
endothelial growth factor (VEGF) in aged human choroid and eyes
with age-related macular degeneration. Exp Eye Res 2006; 82 (1):
99-110.
36. Campochiaro PA, Nguyen QD, Shah SM, KleinML, Holz E, Frank
RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R,
Wei LL. Adenoviral vector-delivered pigment epithelium-derived
factor for neovascular age-related macular degeneration: results of a
phase I clinical trial. Hum Gene Ther 2006; 17 (2): 167-176.
37. Diago T, Pulido JS, Molina JR, Collett LC, Link TP, Ryan EH Jr.
Ranibizumab combined with low-dose sorafenib for exudative age-
related macular degeneration. Mayo Clin Proc 2008; 83 (2): 231-
234.
38. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan
JL. Statin and aspirin therapy are associated with decreased rates of
choroidal neovascularization among patients with age-related macu-
lar degeneration. Am J Ophthalmol 2004; 137 (4): 615-624.
39. Fischer T. Az idoskori maculadegeneráció megelozésének és pre-
ventív terápiájának az újabb kórélettani és klinikai észlelésekre
alapozott lehetséges stratégiája. [A new possible strategy for pre-
vention and preventive treatment of age-related macular degen-
eration resting on recent clinical and pathophysiological observa-
tions]. Orv Hetil 2009; 150 (11): 503-512.
40. Sheidow PL, Hooper PJ, Kertes CE, Schwartz DAL, Maberley P,
Ma BJ, Hinz M. Greve MTS. Tennant SG. Shortt TG. Combina-
tion Therapy in Neovascular Age-Related Macular Degeneration
(amd): A Three-Armed, Randomized, Prospective Clinical Trial
of Low Fluence Photodynamic Therapy (rpdt) With Adjunctive
Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy)
versus Rpdt With Adjunctive Avastin (Double Therapy) versus
Monotherapy With Avastin. ARVO. Fort Lauderdale, USA, May
3-7, 2009; E-Abstract 1922-A612.
41. Cardillo JA, Melo LA Jr, Costa RA, Skaf M, Belfort R Jr, Souza-
Filho AA, Farah ME, Kuppermann BD. Comparison of intravit-
real versus posterior sub-Tenon’s capsule injection of triamcinolo-
ne acetonide for diffuse diabetic macular edema. Ophthalmology
2005; 112 (9): 1557-1563.
42. Emerson MV, Lauer AK. Emerging therapies for the treatment of
neovascular age-related macular degeneration and diabetic macu-
lar edema. BioDrugs 2007; 21 (4): 245-257.
43. Kaiser PK. Strategies for inhibiting vascular endothelial growth
factor. Retina 2009; 29 (6) Suppl: S15-S17.
44. Geltzer A, Turalba A, Vedula SS.Surgical implantation of steroids
with antiangiogenic characteristics for treating neovascular age-
related macular degeneration. Cochrane Database Syst Rev. 2007
Oct 17;(4):CD005022.
